Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Income Taxes

Schedule of reconciliation of income tax provision (benefit)

A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the years ended December 31, 2025 and 2024 is as follows:

	Year Ended
	December 31,
	2025				2024
Federal income tax benefit at statutory rate	$	(6,059,381)	21.0	%	$	(5,163,979)	21.0	%
State and local tax, net of federal benefit		—	—	%		—	—	%
Tax Credits
Research and development credit		(1,625,304)	5.6	%		(1,065,647)	4.3	%
Change in valuation allowance		7,460,209	(25.8)	%		6,127,570	(24.9)	%
Nontaxable or Nondeductible Items
Stock-based compensation		252,715	(0.9)	%		81,012	(0.3)	%
Change in fair value of warrants		(29,820)	0.1	%		(372,268)	1.5	%
Nondeductible compensation		—	—	%		392,495	(1.6)	%
Other		1,581	—	%		817	—	%
Effective income tax rate	$	—	0.0	%	$	—	0.0	%

Schedule of significant components of deferred tax assets

Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets are comprised of the following:

	As of December 31,
	2025		2024
Net operating loss carryforwards	$	18,213,829	$	13,634,896
Stock compensation		4,531,448		4,390,635
Capitalized research and development		940,319		1,137,406
Section 174		15,215,610		12,802,738
Research and development credit carryforwards		6,823,328		5,198,123
Other		85,021		76,757
Total deferred tax assets		45,809,555		37,240,555
Less valuation allowance		(45,809,555)		(37,240,555)
Net deferred taxes	$	—	$	—